GPH Stock Overview
A biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Galmed Pharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.74 |
| 52 Week High | US$5.50 |
| 52 Week Low | US$2.74 |
| Beta | 0.80 |
| 11 Month Change | 0% |
| 3 Month Change | -21.38% |
| 1 Year Change | -12.98% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| GPH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | -13.0% | -17.2% | 8.2% |
Return vs Industry: GPH exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: GPH underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| GPH volatility | |
|---|---|
| GPH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GPH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine GPH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 6 | Allen Baharaff | www.galmedpharma.com |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
Galmed Pharmaceuticals Ltd. Fundamentals Summary
| GPH fundamental statistics | |
|---|---|
| Market cap | €3.98m |
| Earnings (TTM) | -€6.07m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs GPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$6.32m |
| Earnings | -US$6.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GPH perform over the long term?
See historical performance and comparison